Solventum files 8-K, provides Q3 2025 results press release

Rhea-AI Filing Summary

Solventum Corporation furnished an update on its business by reporting third‑quarter 2025 results and providing the related press release as Exhibit 99.1 under Item 2.02 of a Form 8‑K. The exhibit contains the detailed financial results and commentary. The filing notes the press release is furnished, not filed, under the Exchange Act.

FALSE000196473800019647382025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 6, 2025

SOLVENTUM CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware

File No. 001-41968

92-2008841

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota

55144

(Address of Principal Executive Offices)

(Zip Code)

(Registrant’s Telephone Number, Including Area Code) (651) 733-1110

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $.01 Per Share

SOLV

New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.     ☐

Item 2.02. Results of Operations and Financial Condition

On November 6, 2025, Solventum issued a press release reporting third-quarter 2025 financial results (attached hereunder as Exhibit 99.1 and incorporated herein by reference).

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Press Release, dated as of November 6, 2025, of Solventum Corporation (furnished pursuant to Item 2.02 hereof)
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			SOLVENTUM CORPORATION
			By:			/s/ Matthew M. Rice
						Matthew M. Rice
						Vice President, Associate General Counsel & Assistant Secretary

Dated: November 6, 2025

FAQ

What did Solventum (SOLV) announce in this 8-K?

Solventum furnished a press release reporting its third‑quarter 2025 financial results under Item 2.02.

Where can I find the detailed Q3 2025 results for SOLV?

The full details are in Exhibit 99.1, which contains the press release with Q3 2025 results.

Is the press release considered filed or furnished?

It is furnished pursuant to Item 2.02 of the Exchange Act.

Which exhibit includes the Solventum Q3 2025 press release?

Exhibit 99.1 includes the press release.

What is the form type for this Solventum disclosure?

It is a Form 8-K.

Does the 8-K include financial statements?

It includes Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL tags).